MEI Pharma Bets Big on Litecoin: Corporate Treasury Move Sparks 20% LTC Surge
Another day, another company playing hedge fund with shareholder money—but this time, crypto wins.
MEI Pharma just triggered a Litecoin rally by allocating treasury reserves to LTC, proving even biotech firms now see digital silver as safer than FDA approvals.
The move follows MicroStrategy’s Bitcoin playbook, but with a twist: while gold 2.0 (BTC) hoards institutional interest, Litecoin’s payment-focused design actually gets used. MEI’s vote of confidence sent LTC up 20% intraday—because nothing says ‘financial innovation’ like a pharma company moonlighting as a crypto fund.
Key details remain opaque (naturally), but the market isn’t waiting. Litecoin whales are circling, and retail FOMO is brewing. Will this end like Tesla’s Bitcoin U-turn or become a corporate treasury trend? Either way, it’s 2025—where balance sheets double as trading desks and ‘long-term holds’ last until next earnings call.
LTC rallied to a three-month high with peak volumes after MEI Pharma completed and announced its first treasury purchase. | Source: Coingecko
Litecoin remains one of the most widely transacted coins, with representation on major exchanges and brokerages. LTC has also remained the most popular crypto of choice on BitPay. Despite its long-running history, it failed to break out to a new all-time high. Its exposure as a treasury asset and an eventual ETF asset sparks hopes of rising to a high price range after years of depressed market prices.
MEI Pharma completed its first LTC acquisition
Two weeks after announcing its treasury plans, MEI Pharma completed its first acquisition. The company added 929,548 LTC to its portfolio for an average price of $107.58, below the current market prices.
The market did not appear to be primed for the effect of MEI Pharma, as the company managed to acquire the tokens during a recent period of depressed market prices.
The strategic LTC purchase was developed with the guidance of Litecoin’s creator and MEI board member Charlie Lee, who rejoined the project after stepping aside from leadership roles in 2018. MEI Pharma is also guided by crypto investment company GSR with robust governance and market expertise.
“Litecoin has long embodied sound, scalable, and decentralized money,’ said Lee. ‘By initiating this strategy, MEI is taking a clear, institutional step forward that recognizes Litecoin’s role as both a reserve asset and an integral part of global financial systems.”
Litecoin was launched with no premine, though earlier whales may hold significant wallets. The coin is used on Robinhood, PayPal and Venmo due to its reliability and constant uptime for 13 years.
MEI Pharma to rebrand as a Litecoin supporter
In the coming weeks, MEI Pharma will rebrand to reflect its support for LTC and its identity as a treasury company. Following the announcement, MEI Pharma shares recovered to $5.30, gaining a net 87% over the past six months.
The company aims to expand into Litecoin mining activities, in addition to long-term financial innovation. Litecoin mining remains competitive, but allows for the addition of new companies with a still accessible network. The coin reached 2.6 PH/s, close to its all-time mining peak.
MEI Pharma will retain its pre-clinical trials, testing drug candidates for additional research and true trials.
Cryptopolitan Academy: Tired of market swings? Learn how DeFi can help you build steady passive income. Register Now
